Organization
Genentech, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Genentech, Inc.
... NaV1.5, in the heart," said Dan Sutherlin, director of discovery chemistry at Genentech, which has NaV1.7-targeted pain medicines in human clinical trials. "Others are in ...
... the combination of BL-8040 and Merck's KEYTRUDA®; and a collaboration agreement with Genentech, a member of the Roche Group, to investigate the combination of BL-8040 ...
... around the world. The US Biologics License Application (BLA) was submitted by Genentech , a member of Roche Group. "We are pleased that HEMLIBRA, a ...
... Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced ...
... Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced ...
... $482,000 for the first year and slightly less after that, said California-based Genentech, which developed the drug. Genentech, the biotech subsidiary of Swiss drugmaker Roche, ...
... protein degradation, today announced it has expanded its ongoing license agreement with Genentech, a member of the Roche Group, for the development of new therapeutics ...
... Genentech has doubled the size of its alliance with Arvinas, moving the potential ...
... with a $130 million series B just over a year later. RELATED: Ex-Genentech dream team garners $217M to launch neurodegenerative player Denali Denali is focused ...
... clinical trial we are fielding in collaboration with the NSABP Foundation and Genentech were also initiated in the third quarter. This clinical trial, Functional Analysis ...
... in 2016. Revenues for both periods comprise primarily royalty revenues recorded on Genentech and Roche's net sales of Erivedge. Operating expenses were $ 16.9 million ...
... selective and potent inhibitor of the adenosine A2A receptor. Atezolizumab, developed by Genentech, a member of the Roche Group, is a monoclonal antibody designed to ...
... South San Francisco, CA - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today ...
... the combination of BL-8040 and Merck's KEYTRUDA®; and a collaboration agreement with Genentech, a member of the Roche Group, to investigate the combination of BL-8040 ...
... Ian Clark to its Board of Directors. Ian Clark, former CEO of Genentech, will join as an independent director effective immediately. "Ian brings decades of ...
... solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are ...
... Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced ...
... Pal and Thomas Powles. Cobimetinib Highlights Settlement of Arbitration between Exelixis and Genentech Regarding Companies' Collaboration Agreement for Cobimetinib. In July, Exelixis announced a settlement ...
... the combination of BL-8040 and Merck's KEYTRUDA and a collaboration agreement with Genentech, a member of the Roche Group, to investigate the combination of BL-8040 ...
... 602, the Phase 1b/2 clinical trial evaluating the combination of entinostat plus Genentech's PD-L1 inhibitor, TECENTRIQ®, in patients with triple negative breast cancer, is now ...
... in the recently initiated study, Halozyme will earn a $15 million milestone payment.Genentech launching RITUXAN HYCELA(TM)(rituximab/hyaluronidase human) for subcutaneous injection, a combination of rituximab and ...
... quarter of 2017. While we are disappointed that our partnered program with Genentech, GDC-0310, will not enter a Phase 2 trial in the first quarter ...
... in 2016. Revenues for both periods comprise primarily royalty revenues recorded on Genentech and Roche's net sales of Erivedge®. Operating expenses were $16.9 million for ...
... Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today ...
... The fortunes of Roche’s Genentech biologics plant in California, to a large degree, have followed the ebb ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤